Treatment of inflammatory myopathies

被引:0
|
作者
Mastaglia, FL
Phillips, BA
Zilko, P
机构
[1] QUEEN ELIZABETH II MED CTR,DEPT MED,PERTH,WA 6009,AUSTRALIA
[2] QUEEN ELIZABETH II MED CTR,DEPT NEUROL,PERTH,WA 6009,AUSTRALIA
[3] QUEEN ELIZABETH II MED CTR,DEPT CLIN IMMUNOL,PERTH,WA 6009,AUSTRALIA
关键词
inflammatory myopathies; treatment; polymyositis; dermatomyositis; inclusion body myositis;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The treatment of the immune-mediated inflammatory myopathies remains largely empirical. Corticosteroids are usually effective in polymyositis and dermatomyositis but may need to be combined with methotrexate or azathioprine in some patients, Intravenous immunoglobulin (IVIg) is effective as add-on therapy in some patients not adequately controlled with steroids or immunosuppressive agents, but further controlled trials of IVIg are necessary to define the indications and optimal dose regimens. Cyclophosphamide, cyclosporin, or chlorambucil may be effective in patients with refractory polymyositis or dermatomyositis. Low-dose whole body or lymphoid irradiation is a last option in severely disabled patients resistant to all other treatments. As a small proportion of patients with inclusion body myositis respond to corticosteroid or immunosuppressive therapy, a 3-6-month trial of such therapy is justified in this condition. More specific immunotherapy for these disorders awaits identification of the target antigens and further clarification of the immunopathogenetic mechanisms. (C) 1997 John Wiley & Sons, Inc.
引用
收藏
页码:651 / 664
页数:14
相关论文
共 50 条
  • [21] Drugs in induction and treatment of idiopathic inflammatory myopathies
    Iaccarino, Luca
    Bartoloni, Elena
    Gerli, Roberto
    Alunno, Alessia
    Barsotti, Simone
    Cafaro, Giacomo
    Gatto, Mariele
    Talarico, Rosaria
    Tripoli, Alessandra
    Zen, Margherita
    Neri, Rossella
    Doria, Andrea
    AUTOIMMUNITY HIGHLIGHTS, 2014, 5 (03) : 95 - 100
  • [23] Current pharmacological treatment of idiopathic inflammatory myopathies
    Fasano, Serena
    Alves, Sara Custodio
    Isenberg, David A.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (04) : 547 - 558
  • [24] Rituximab treatment in patients with refractory inflammatory myopathies
    Mahler, Elien A. M.
    Blom, Marlies
    Voermans, Nicol C.
    van Engelen, Baziel G. M.
    van Riel, Piet L. C. M.
    Vonk, Madelon C.
    RHEUMATOLOGY, 2011, 50 (12) : 2206 - 2213
  • [25] Experience with intravenous immunoglobulin for the treatment of inflammatory myopathies
    Dalakas, MC
    INTRAVENOUS IMMUNOGLOBULIN: RESEARCH AND THERAPY, 1996, : 275 - 284
  • [26] Idiopathic inflammatory myopathies - Optimum immunosuppressive treatment
    Zilko, PJ
    Mastaglia, FL
    Phillips, BA
    BIODRUGS, 1997, 7 (04) : 262 - 272
  • [27] Treatment of the inflammatory myopathies: update and practical recommendations
    Hengstman, Gerald J. D.
    van den Hoogen, Frank H. J.
    van Engelen, Baziel G. M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (07) : 1183 - 1190
  • [28] Classification and treatment of the juvenile idiopathic inflammatory myopathies
    Rider, LG
    Miller, FW
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 1997, 23 (03) : 619 - +
  • [29] INFLAMMATORY MYOPATHIES
    KINGSTON, WJ
    MOXLEY, RT
    NEUROLOGIC CLINICS, 1988, 6 (03) : 545 - 561
  • [30] Inflammatory Myopathies
    Distad, B. Jane
    Amato, Anthony A.
    Weiss, Michael D.
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2011, 13 (02) : 119 - 130